CMV (DNA detection by Real time PCR Saliva)

Immunity

Report in 192Hrs

At Home

No Fasting Required

Details

Detects CMV viremia.

₹6,845₹9,779

30% OFF

CMV (DNA detection by Real time PCR Saliva) - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Description: This test detects cytomegalovirus (CMV) DNA in saliva using Real-time Polymerase Chain Reaction (PCR). It identifies active viral replication and determines the viral load, providing molecular evidence of CMV infection or reactivation.
- Primary Indications for Testing:
  - Immunocompromised patients (HIV/AIDS with CD4 <50 cells) suspected of CMV infection
  - Organ transplant recipients for surveillance and diagnosis of CMV disease
  - Patients presenting with CMV-related symptoms (fever, oral ulcers, esophagitis)
  - Monitoring of antiviral therapy efficacy in CMV-positive patients
  - Detection of CMV reactivation or viral recrudescence
  - Congenital CMV screening in newborns with symptoms of intrauterine infection
- Timing and Circumstances: Testing is performed when clinical suspicion for CMV exists, during regular surveillance in high-risk populations, or when monitoring response to antiviral treatment. Saliva sampling offers non-invasive, convenient collection for serial monitoring.
Section 2: Normal Range
- Normal/Reference Values:
  - Negative/Undetectable: CMV DNA not detected or below the limit of detection (typically <100-200 copies/mL, depending on assay)
  - Positive: CMV DNA detected and quantifiable
- Units of Measurement: copies/mL (copies per milliliter of saliva)
- Result Interpretation:
  - Negative Result: No CMV DNA detected; indicates either absence of CMV infection, latent infection without reactivation, or successful viral suppression with antiviral therapy
  - Positive Result: CMV DNA detected; indicates active viral replication and potential CMV disease. Viral load quantification indicates severity and therapeutic urgency
  - Borderline/Low Positive: Viral load near lower limit of detection; may indicate early reactivation, viral shedding, or early treatment response requiring clinical correlation and possible repeat testing
Section 3: Interpretation
- Detailed Result Interpretation:
  - Undetectable (<100-200 copies/mL): No active CMV replication; patient is CMV negative or latently infected without current viral shedding
  - Low Positive (100-1,000 copies/mL): Mild viral replication; early reactivation, early infection, or viral shedding in previously infected individuals; close clinical monitoring and consideration of antiviral therapy recommended
  - Moderate Positive (1,000-100,000 copies/mL): Significant viral replication indicating active CMV disease; antiviral therapy typically indicated; assess for end-organ disease manifestations
  - High Positive (>100,000 copies/mL): Substantial viral burden indicating severe CMV disease; urgent initiation of antiviral therapy warranted; high risk for end-organ disease progression
- Factors Affecting Results:
  - Immune status: CD4 count in HIV patients (higher risk of CMV with CD4 <50); degree of immunosuppression in transplant recipients
  - Antiviral therapy: Ganciclovir, valganciclovir, foscarnet, and cidofovir reduce CMV DNA levels
  - Specimen quality: Saliva quantity and purity may affect PCR sensitivity; contamination can lead to false results
  - Viral load fluctuations: CMV DNA levels can vary naturally over time and between different body compartments
  - CMV resistance: Prior or current antiviral use may select for drug-resistant CMV strains with altered viral dynamics
- Clinical Significance: CMV DNA detection by Real-time PCR is highly specific and sensitive for identifying active CMV replication. Viral load correlates with disease severity and risk of end-organ manifestations (retinitis, colitis, esophagitis, encephalitis). Serial monitoring enables assessment of treatment efficacy and prediction of clinical outcomes.
Section 4: Associated Organs
- Primary Organ Systems Involved:
  - Oral cavity and salivary glands (primary site of saliva sampling)
  - Gastrointestinal tract (esophagus, stomach, colon)
  - Ocular system (retina)
  - Central nervous system (brain, spinal cord)
  - Pulmonary system (lungs)
  - Multiple organ systems in disseminated disease
- Common Diseases Associated with Abnormal Results:
  - CMV Retinitis: Progressive inflammation and necrosis of the retina causing vision loss; primarily in advanced AIDS
  - CMV Esophagitis: Inflammation and ulceration of the esophagus causing dysphagia and chest pain
  - CMV Colitis: Inflammation of the colon with diarrhea, abdominal pain, and potential perforation
  - CMV Encephalitis/Meningitis: CNS infection causing confusion, altered mental status, seizures, and neurological deficits
  - CMV Pneumonitis: Lung inflammation causing dyspnea, hypoxemia, and respiratory compromise
  - CMV Gingivitis/Oral Ulcers: Painful ulcerations in the oral cavity detectable in saliva samples
  - Congenital CMV Infection: Intrauterine infection causing microcephaly, hearing loss, intellectual disability, and developmental delays
- Potential Complications of Abnormal Results (Positive CMV):
  - Progressive end-organ disease if untreated (blindness from retinitis, bowel perforation from colitis)
  - Immune reconstitution inflammatory syndrome (IRIS) in HIV patients following immune recovery
  - Development of antiviral drug resistance with prolonged or inadequate therapy
  - Chronic organ dysfunction and reduced quality of life
  - Graft loss in transplant recipients if CMV disease develops
Section 5: Follow-up Tests
- Additional Tests Based on Positive CMV Saliva PCR:
  - CMV DNA PCR from Plasma/Serum: Confirms systemic viremia and assesses disease severity; higher predictive value for end-organ disease
  - CMV DNA PCR from Cerebrospinal Fluid (CSF): If CNS disease suspected; essential for diagnosing CMV encephalitis or meningitis
  - CMV DNA PCR from Tissue Biopsy: If end-organ disease suspected (esophageal, colonic, or retinal involvement); provides direct evidence of CMV tissue infection
  - Ophthalmologic Examination: Dilated fundoscopy to screen for CMV retinitis; essential in patients with CD4 <50 or positive CMV viremia
  - Endoscopy with Biopsy: Esophagogastroduodenoscopy (EGD) or colonoscopy if GI symptoms present; allows visualization and histopathological confirmation
  - CD4 Count (in HIV patients): Establishes baseline immune status and risk for CMV disease progression
  - CMV Pp65 Antigenemia Assay: Alternative test for detecting CMV antigen in blood; useful for serial monitoring in some centers
- Monitoring Frequency for Ongoing CMV Management:
  - Active CMV Disease: Repeat CMV DNA PCR every 1-2 weeks during antiviral therapy until undetectable
  - Maintenance Suppressive Therapy: Monthly or every 3 months depending on clinical circumstances
  - Post-Treatment Monitoring: Every 3-6 months for 1 year to detect early reactivation
  - Transplant Surveillance: According to institutional protocols, often monthly to quarterly
- Complementary and Related Tests:
  - CMV IgG and IgM Serology: Determines prior exposure and recent primary infection
  - CMV Resistance Testing (ganciclovir/foscarnet resistance mutations): If treatment failure occurs
  - HIV Viral Load and CD4 Count: Essential for managing CMV in HIV patients; immune reconstitution is key to CMV control
  - Renal Function Tests: Monitor for antiviral drug toxicity (foscarnet and cidofovir nephrotoxicity)
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for this test
- Special Preparation Instructions:
  - Prior to Collection (Avoid 30 minutes before sample): Eating, drinking, smoking, or chewing gum
  - Oral Hygiene: Avoid brushing teeth, mouthwash, or rinsing mouth 30 minutes before sample collection to prevent contamination and dilution of saliva
  - Medications: Continue all medications as prescribed; antiviral medications should NOT be discontinued unless directed by physician
  - Collection Method: Unstimulated saliva collection into sterile tube; typically 2-5 mL required depending on laboratory specifications
  - Timing of Collection: Sample can be collected at any time of day; morning collection often preferred for consistency
  - Storage and Transport: Refrigerate sample at 2-8°C if not processed immediately; transport to laboratory within 2-4 hours to maintain sample integrity
  - Avoid: Freezing saliva samples at -20°C or below unless using appropriate preservative medium; contamination with blood (gingival bleeding); collection during acute upper respiratory infection if possible
- Patient Comfort Considerations: This test is non-invasive and highly acceptable to patients; no needle stick, no pain, and minimal discomfort; makes it ideal for serial monitoring and pediatric populations

How our test process works!